Reported by Weng Patrick Atokor l Journalist at Weng Global
Nigeria has been urged to accelerate local pharmaceutical manufacturing, strengthen drug regulation and increase investment in research and innovation as concerns grow over the country’s dependence on imported medicines and its vulnerability to disruptions in global supply chains.
The call comes amid renewed efforts by the World Health Organisation (WHO), the Nigeria Academy of Pharmacy and other pharmaceutical stakeholders to strengthen Nigeria’s capacity to manufacture essential medicines and develop a more self-reliant healthcare system.
The Nigeria Academy of Pharmacy has warned that the country’s dependence on imported medicines and pharmaceutical technologies poses a significant threat to national health security, economic independence and the availability of essential healthcare products.
The academy’s President and Chairman of its Governing Council, Professor Lere Baale, said Nigeria must treat pharmaceutical development as a national priority, arguing that the country’s health security is closely connected to its scientific capabilities, economic strength and sovereignty.
His position was communicated ahead of the academy’s 2026 Annual General Meeting and Investiture of New Fellows, scheduled for November 16 and 17 in Lagos.
The gathering is focused on strengthening the pharmaceutical sector through innovation, local manufacturing, research, technology adoption and improved regulatory standards.
WHO Calls Attention to Pharmaceutical Innovation and Health Security
The World Health Organisation’s Representative and Head of Mission in Nigeria, Dr Pavel Ursu, was scheduled to deliver the keynote address at the academy’s November 17 investiture ceremony.
The event is organised around the theme, Pharmacy for National Health Security: Advancing Innovation, Medicine Sovereignty and Sustainable Healthcare.
The participation of the WHO representative highlights the importance of pharmaceutical innovation and stronger domestic manufacturing capacity in addressing healthcare challenges.
Nigeria, like several African countries, faces challenges associated with dependence on foreign pharmaceutical manufacturers, particularly when international supply chains experience disruptions.
The COVID-19 pandemic exposed weaknesses in global access to medicines, vaccines and other essential medical supplies, demonstrating the importance of developing domestic and regional production capabilities.
For Nigeria, strengthening pharmaceutical manufacturing could help reduce exposure to international supply disruptions while improving the availability of essential medicines.
However, achieving meaningful progress will require more than establishing additional factories. Investment in scientific research, pharmaceutical technology, skilled professionals, quality assurance and effective regulation will also be necessary.
Nigeria’s Dependence on Imported Medicines Raises Concerns
Nigeria’s reliance on imported medicines remains one of the major challenges confronting its pharmaceutical industry.
Available industry estimates indicate that domestic manufacturers supply only a portion of the country’s pharmaceutical requirements, leaving a substantial share dependent on foreign production.
The Nigeria Academy of Pharmacy has warned that this dependence creates vulnerabilities for the country’s healthcare system.
A report published by Health Digest on November 12 indicated that Nigeria produces approximately 20 per cent of its medicines locally while importing the remaining 80 per cent.
Other industry reports have placed the import-dependent share above 70 per cent, highlighting differences in available estimates.
Regardless of the precise figure, the country’s dependence on imported pharmaceutical products remains a significant concern.
Import dependence also exposes the pharmaceutical market to exchange-rate fluctuations, international price movements, transportation costs and changes in the availability of raw materials.
When the naira weakens against major international currencies, the cost of importing medicines and pharmaceutical inputs can increase, potentially placing additional pressure on manufacturers, distributors, healthcare providers and patients.
The situation is particularly important in a country where access to affordable healthcare remains a major concern for millions of citizens.
Federal Government Sets 70% Local Production Target for 2030
Nigeria’s efforts to strengthen domestic pharmaceutical manufacturing are also supported by a Federal Government target to produce at least 70 per cent of essential healthcare products locally by 2030.
The Minister of State for Health and Social Welfare, Dr Iziaq Adekunle Salako, announced the target during the opening of the eighth Nigeria Pharma Manufacturers Expo in Lagos on September 28, 2026.
The target forms part of the Federal Government’s broader strategy to strengthen medicine security and develop Nigeria’s healthcare value chain.
According to the Federal Ministry of Information and National Orientation, the Presidential Initiative to Unlock the Healthcare Value Chain (PVAC) has secured approximately $2 billion in financing commitments at single-digit interest rates.
The initiative also had about 50 Nigerian healthcare companies involved in advanced funding discussions at the time of the announcement.
Salako disclosed that 87 local manufacturers were benefiting from the implementation of the Presidential Executive Order, which introduced zero tariffs on pharmaceutical machinery, active pharmaceutical ingredients and excipients across almost 1,000 Harmonised System codes.
These measures are intended to reduce production costs and encourage investment in domestic manufacturing.
The government has also identified the production of active pharmaceutical ingredients, vaccines, biologics, diagnostics and other essential healthcare products as important areas for expansion.
The 70 per cent target is a government policy objective for 2030, rather than an established production achievement.
Its success will depend on whether the announced incentives translate into increased manufacturing capacity, reliable production and improved access to affordable medicines.
Research and Innovation Remain Critical to Pharmaceutical Development
Beyond manufacturing, pharmaceutical research and development have emerged as important priorities in efforts to strengthen Nigeria’s healthcare system.
The Nigeria Academy of Pharmacy has called for increased investment in scientific research, technological innovation and collaboration among universities, pharmaceutical companies and government institutions.
Research is particularly important in developing new medicines, improving existing treatments and identifying opportunities to utilise locally available resources.
Nigeria also has opportunities to expand research into phytomedicine, which involves the scientific development and application of plant-based medicinal products.
However, the development of such products requires scientific validation, clinical evidence, quality control and regulatory approval.
The Federal Government has similarly emphasised the importance of investing in Nigeria’s phytomedicinal resources.
At the September Nigeria Pharma Manufacturers Expo, Salako called for greater investment in research and development, stressing that genuine pharmaceutical localisation must extend beyond importing ingredients and packaging finished products locally.
He said the country needed to build capabilities across the entire pharmaceutical value chain, including research, raw materials, formulation, quality assurance, manufacturing, packaging and distribution.
This approach would allow Nigeria to develop more sophisticated domestic pharmaceutical capabilities rather than remain dependent on foreign technologies and production inputs.
Regulatory Standards and Quality Control
Stronger pharmaceutical regulation will also be essential to achieving the country’s manufacturing ambitions.
As domestic production expands, regulatory institutions must ensure that locally manufactured medicines meet internationally recognised safety, quality and efficacy standards.
The National Agency for Food and Drug Administration and Control (NAFDAC) plays a central role in regulating medicines, pharmaceutical manufacturing facilities and the distribution of healthcare products in Nigeria.
Regulatory improvements are important not only for protecting Nigerian patients but also for helping local manufacturers compete in international markets.
Manufacturers seeking to expand across Africa must demonstrate that their products meet appropriate quality standards and comply with the regulatory requirements of destination markets.
The WHO’s support for stronger regulatory systems and pharmaceutical manufacturing capacity is therefore relevant to Nigeria’s broader ambition of improving medicine security.
The challenge is to ensure that efforts to increase domestic production do not compromise the quality and safety of medicines available to the public.
Financing and Infrastructure Could Determine Success
Despite the government’s policy commitments, Nigeria’s pharmaceutical manufacturing ambitions face several structural challenges.
High energy costs, inadequate infrastructure, limited access to affordable financing, foreign exchange instability and dependence on imported raw materials have historically constrained local manufacturers.
Pharmaceutical production requires reliable electricity, specialised equipment, technically skilled workers and strict environmental and quality-control systems.
Manufacturers must also be able to obtain active pharmaceutical ingredients and other materials required for producing medicines.
Where these inputs remain heavily dependent on foreign suppliers, domestic production may continue to face vulnerabilities even when finished products are manufactured within Nigeria.
The availability of long-term financing will therefore be important in supporting companies seeking to expand production capacity, modernise factories and invest in research.
Government incentives must also be implemented consistently to provide investors with confidence that policies supporting local manufacturing will remain sustainable.
Why Nigeria’s Pharmaceutical Independence Matters
The drive towards greater local medicine production has implications beyond the pharmaceutical industry.
For ordinary Nigerians, stronger domestic manufacturing could contribute to more reliable medicine supplies and reduce some of the risks associated with international supply disruptions.
It could also create employment opportunities for pharmacists, scientists, engineers, laboratory professionals, manufacturing workers and other skilled personnel.
For the Nigerian economy, an expanded pharmaceutical industry could reduce dependence on imported finished medicines, encourage technology transfer and create opportunities for exports.
The wider African pharmaceutical market also presents opportunities for Nigerian manufacturers.
Through the African Continental Free Trade Area (AfCFTA), Nigeria could potentially expand the reach of locally manufactured medicines into other African markets, provided manufacturers meet the relevant regulatory and quality requirements.
Regional cooperation could also support shared research initiatives, manufacturing partnerships and more efficient pharmaceutical supply chains.
However, pharmaceutical independence should not be measured simply by the number of medicines produced within national borders.
The more important indicators include the quality of locally manufactured products, affordability, access, technological capacity, research investment and the ability to maintain production during international emergencies.
What Happens Next?
The Nigeria Academy of Pharmacy’s 2026 Annual General Meeting and Investiture of New Fellows took place in Lagos on November 16 and 17, with the November 17 ceremony scheduled to feature the keynote address by WHO Representative Dr Pavel Ursu.
The gathering provides an opportunity for pharmaceutical professionals, policymakers, researchers, manufacturers and development partners to examine strategies for improving Nigeria’s pharmaceutical capacity.
The Federal Government’s 2030 local production target will also require continued implementation of the Presidential Initiative to Unlock the Healthcare Value Chain and other manufacturing incentives.
Sustained collaboration among government institutions, pharmaceutical companies, universities, regulators and international development partners will be necessary to translate policy commitments into measurable improvements.
For Nigeria, the central challenge is moving from dependence on imported medicines towards a pharmaceutical industry capable of meeting domestic healthcare needs while competing in regional and international markets.
The country’s ability to achieve this ambition will depend on consistent investment, scientific innovation, effective regulation and the development of a sustainable manufacturing ecosystem.
Weng Global – Stories beyond borders
Sources
- THISDAY – Pharmacy Academy Urges Nigeria to Prioritize Health Security, Local Drug Production.
- The Guardian – WHO Representative to Deliver Keynote at NAPHARM 2026 Investiture.
- Federal Ministry of Information and National Orientation – Salako Reaffirms FG’s Commitment to Pharmaceutical Manufacturing, Medicine Security.
- Premium Times – FG Targets 70% Local Production of Essential Medicines by 2030.
- PharmaNews – Pharmacy Academy Urges Urgent Action to Safeguard Medicine Security.
- Health Digest – Pharmacy Academy Urges FG to Cut Dependence on Imported Medicines.